Publications by authors named "Hubert Borell"

5Publications

Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.

Drug Metab Dispos 2020 10 14;48(10):873-885. Epub 2020 Jul 14.

PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., G.R., U.P., H.B., A.M., G.C., S.Z.); Preclinical Safety, Novartis Pharma AG, Basel, Switzerland (R.H.); Novartis Global Discovery Chemistry, Novartis Pharma AG, Basel, Switzerland (K.S., A.M.); and PRA Health Sciences, The Netherlands (J.J.v.L.).

View Article and Find Full Text PDF
October 2020

Metabolism and Disposition of Siponimod, a Novel Selective S1P/S1P Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism.

Drug Metab Dispos 2018 07 7;46(7):1001-1013. Epub 2018 May 7.

PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., R.N., W.L., K.S., S.A.-S., E.L., H.B., A.D.J., A.M., G.C., A.G.), and PRA Health Sciences, Raleigh, North Carolina (S.P.M.).

View Article and Find Full Text PDF
July 2018

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.

Eur J Clin Pharmacol 2018 Apr 22;74(4):455-464. Epub 2017 Dec 22.

PK Sciences, Novartis Institutes for Biomedical Research (NIBR), Fabrikstrasse 14, 202.3, CH-4002, Basel, Switzerland.

View Article and Find Full Text PDF
April 2018

CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.

Drug Metab Dispos 2011 Feb 2;39(2):191-8. Epub 2010 Nov 2.

Novartis Institutes for BioMedical Research, Drug Metabolism and Pharmacokinetics, Basel, Switzerland.

View Article and Find Full Text PDF
February 2011